Advances in medical treatment of breast cancer in 2022

Jingtong Zhai, Yun Wu, Fei Ma, Virginia Kaklamani, Binghe Xu

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations

Abstract

Breast cancer has replaced lung cancer as the most common malignancy worldwide. The 5-year survival rate of breast cancer has reached 90%. Systemic treatment of breast cancer has developed into a mature system including chemotherapy, targeted therapy, endocrine therapy and immunotherapy. This article summarizes the annual progress of breast cancer chemotherapy, targeted therapy, endocrine therapy and immunotherapy in 2022, providing valuable information for future research to better guide individualized treatment of breast cancer, thereby improving the prognosis and quality of life of breast cancer patients.

Original languageEnglish (US)
Pages (from-to)1-17
Number of pages17
JournalCancer Innovation
Volume2
Issue number1
DOIs
StatePublished - Feb 2023
Externally publishedYes

Keywords

  • breast cancer
  • chemotherapy
  • endocrine therapy
  • immunotherapy
  • targeted therapy

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
  • Pharmacology (medical)
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Advances in medical treatment of breast cancer in 2022'. Together they form a unique fingerprint.

Cite this